Takeda Pharmaceutical

More reviews (2)

Live  

Takeda Pharmaceutical Company Limited is a global, research-based pharmaceutical company headquartered in Japan. The company was founded in 1781 and has a rich history of over 200 years of continuous operation.
Takeda is one of the world's largest pharmaceutical companies, with a focus on developing and delivering innovative medicines to patients in more than 80 countries and regions around the world. The company's research and development efforts are focused on four therapeutic areas: oncology, gastroenterology, neurology, and rare diseases.
With a commitment to improving the health and well-being of people worldwide, Takeda strives to develop safe and effective medicines to treat a wide range of diseases and conditions. In addition to its core therapeutic areas, the company also has a growing portfolio in vaccines and consumer healthcare.
Takeda's corporate philosophy, "Takeda-ism," emphasizes its dedication to ethical and responsible business practices, as well as its commitment to patients, employees, and the global community.
Today, Takeda has a team of more than 49,000 employees worldwide, and its research and development efforts are led by a diverse network of scientists, researchers, and physicians who collaborate globally to drive innovation and advancement in the pharmaceutical industry.

Takeda Pharmaceutical Company is a big business that helps people feel better when they’re sick. They make medicines and treatments for various health problems, like when someone has a headache, a stomach issue, or even more serious things like cancer.
Think of Takeda like a team of doctors and scientists who work together to find new ways to help people. They do a lot of research to create new medicines, and they also find ways to improve existing ones. Once they develop a medicine, they have to test it to make sure it works well and is safe for people to use.
So, how does Takeda make money? Well, once they create a new medicine and get permission from the government to sell it, they can sell it to hospitals, pharmacies, and doctors. When people buy these medicines to help them feel better, Takeda earns money from those sales. The more people who need their medicines, the more money they can make.
Now, why is Takeda successful? There are a few reasons. First, they focus a lot on research and development, which means they’re always looking for better treatments. They also have a strong reputation for making high-quality medicines. Plus, they operate in many countries around the world, which means they can reach more people.
As for the future, there are a few reasons why Takeda is likely to keep being successful. They keep investing in new technologies and research to find new medicines, and that helps them stay ahead of their competition. Also, as people around the world continue to need help with their health issues, companies like Takeda will always have a demand for their medicines. So, as long as they keep working hard and coming up with new ideas, they will likely continue to be successful!

VGhlcmUgYX JlIHNldmVy YWwgYXNwZW N0cyB0aGF0 IG1ha2UgVG FrZWRhIFBo YXJtYWNldX RpY2FsIHN0 YW5kIG91dC BhcyBhIGNv bXBhbnk6PG JyPjEuIExv bmcgSGlzdG 9yeTogVGFr ZWRhIFBoYX JtYWNldXRp Y2FsIHdhcy Bmb3VuZGVk IGluIDE3OD EsIG1ha2lu ZyBpdCBvbm Ugb2YgdGhl IG9sZGVzdC Bjb21wYW5p ZXMgaW4gSm FwYW4gYW5k IHRoZSB3b3 JsZC4gVGhp cyBsb25nIG hpc3Rvcnkg aGFzIGFsbG 93ZWQgdGhl IGNvbXBhbn kgdG8gZ2Fp biBleHRlbn NpdmUga25v d2xlZGdlIG FuZCBleHBl cmllbmNlIG luIHRoZSBw aGFybWFjZX V0aWNhbCBp bmR1c3RyeS 48YnI+Mi4g SW50ZXJuYX Rpb25hbCBQ cmVzZW5jZT ogVGFrZWRh IGhhcyBhIH N0cm9uZyBn bG9iYWwgcH Jlc2VuY2Us IHdpdGggb3 BlcmF0aW9u cyBpbiBvdm VyIDgwIGNv dW50cmllcy BhbmQgcmVn aW9ucyB3b3 JsZHdpZGUu IEl0IGhhcy BhIHN0cm9u ZyBmb2N1cy BvbiBlbWVy Z2luZyBtYX JrZXRzLCBl c3BlY2lhbG x5IGluIEFz aWEsIHdoZX JlIHRoZSBj b21wYW55IG hhcyBhIGxl YWRpbmcgcG 9zaXRpb24g aW4gdGhlIH BoYXJtYWNl dXRpY2FsIG luZHVzdHJ5 Ljxicj4zLi BEaXZlcnNl IFBvcnRmb2 xpbzogVGFr ZWRhIGhhcy BhIGRpdmVy c2UgcG9ydG ZvbGlvIG9m IHByb2R1Y3 RzLCBjb3Zl cmluZyBhIH dpZGUgcmFu Z2Ugb2YgdG hlcmFwZXV0 aWMgYXJlYX MsIGluY2x1 ZGluZyBvbm NvbG9neSwg Z2FzdHJvZW 50ZXJvbG9n eSwgbmV1cm 9zY2llbmNl LCByYXJlIG Rpc2Vhc2Vz LCBhbmQgdm FjY2luZXMu IFRoaXMgZG l2ZXJzaWZp Y2F0aW9uIG hlbHBzIHRo ZSBjb21wYW 55IG1pdGln YXRlIHJpc2 tzIGFuZCBt YWludGFpbi BhIHN0YWJs ZSByZXZlbn VlIHN0cmVh bS48YnI+NC 4gSW5ub3Zh dGlvbjogVG FrZWRhIGhh cyBhIHN0cm 9uZyBmb2N1 cyBvbiByZX NlYXJjaCBh bmQgZGV2ZW xvcG1lbnQg KFImRCksIH dpdGggYSBz aWduaWZpY2 FudCBpbnZl c3RtZW50IG luIGN1dHRp bmctZWRnZS B0ZWNobm9s b2d5IGFuZC Bjb2xsYWJv cmF0aW9ucy B3aXRoIGV4 dGVybmFsIH BhcnRuZXJz LiBUaGUgY2 9tcGFueSBh bHNvIGhhcy BhIHJvYnVz dCBwaXBlbG luZSBvZiBw b3RlbnRpYW wgbmV3IHRy ZWF0bWVudH MsIGVuc3Vy aW5nIGl0cy Bsb25nLXRl cm0gZ3Jvd3 RoLjxicj41 LiBDb3Jwb3 JhdGUgU29j aWFsIFJlc3 BvbnNpYmls aXR5OiBUYW tlZGEgaXMg Y29tbWl0dG VkIHRvIGNv cnBvcmF0ZS ByZXNwb25z aWJpbGl0eS BhbmQgaGFz IHNldCBhbW JpdGlvdXMg Z29hbHMgdG 8gcmVkdWNl IGl0cyBlbn Zpcm9ubWVu dGFsIGltcG FjdCBhbmQg aW1wcm92ZS BhY2Nlc3Mg dG8gaGVhbH RoY2FyZSBn bG9iYWxseS 4gVGhlIGNv bXBhbnkgYW xzbyBoYXMg dmFyaW91cy Bwcm9ncmFt cyBpbiBwbG FjZSB0byBz dXBwb3J0IG NvbW11bml0 aWVzIGFuZC Bwcm9tb3Rl IGRpdmVyc2 l0eSBhbmQg aW5jbHVzaW 9uLjxicj42 LiBWYWx1ZX MtRHJpdmVu IEN1bHR1cm U6IFRha2Vk YSdzIGNvcm UgdmFsdWVz LCBzdWNoIG FzICJpbnRl Z3JpdHksIG ZhaXJuZXNz LCBhbmQgaG 9uZXN0eSIg YW5kICJwdX R0aW5nIHRo ZSBwYXRpZW 50IGZpcnN0 LCIgYXJlIG RlZXBseSBp bmdyYWluZW QgaW4gaXRz IGNvcnBvcm F0ZSBjdWx0 dXJlLiBUaG lzIHN0cm9u ZyBldGhpY2 FsIGZvdW5k YXRpb24gZ3 VpZGVzIHRo ZSBjb21wYW 55J3MgZGVj aXNpb24tbW FraW5nIGFu ZCBkcml2ZX MgaXRzIGNv bW1pdG1lbn QgdG8gbWFr aW5nIGEgcG 9zaXRpdmUg aW1wYWN0IG luIHRoZSB3 b3JsZC48Yn I+SW4gY29u Y2x1c2lvbi wgVGFrZWRh IFBoYXJtYW NldXRpY2Fs J3MgbG9uZy BoaXN0b3J5 LCBnbG9iYW wgcHJlc2Vu Y2UsIGRpdm Vyc2UgcG9y dGZvbGlvLC Bmb2N1cyBv biBpbm5vdm F0aW9uLCBj b21taXRtZW 50IHRvIHNv Y2lhbCByZX Nwb25zaWJp bGl0eSwgYW 5kIHZhbHVl cy1kcml2ZW 4gY3VsdHVy ZSBhbGwgbW FrZSBpdCBh IHVuaXF1ZS BhbmQgc3Vj Y2Vzc2Z1bC Bjb21wYW55 IGluIHRoZS BwaGFybWFj ZXV0aWNhbC BpbmR1c3Ry eS4=

VGhlIFRha2 VkYSBQaGFy bWFjZXV0aW NhbCBjb21w YW55J3MgYn VzaW5lc3Mg bW9kZWwgaX MgYmFzZWQg b24gcmVzZW FyY2hpbmcs IGRldmVsb3 BpbmcsIG1h bnVmYWN0dX JpbmcsIGFu ZCBtYXJrZX RpbmcgcGhh cm1hY2V1dG ljYWwgcHJv ZHVjdHMuIF RoZSBjb21w YW55IGZvY3 VzZXMgb24g dGhlIGZvbG xvd2luZyBr ZXkgYXJlYX M6PGJyPjEu IFJlc2Vhcm NoIGFuZCBk ZXZlbG9wbW VudDogVGFr ZWRhIGludm VzdHMgaGVh dmlseSBpbi ByZXNlYXJj aCBhbmQgZG V2ZWxvcG1l bnQgdG8gZG lzY292ZXIg YW5kIGRldm Vsb3AgbmV3 IG1lZGljaW 5lcyBmb3Ig ZGlzZWFzZX Mgd2l0aCBo aWdoIHVubW V0IG1lZGlj YWwgbmVlZH MuPGJyPjIu IE1hbnVmYW N0dXJpbmc6 IFRha2VkYS BoYXMgYSBn bG9iYWwgbm V0d29yayBv ZiBtYW51Zm FjdHVyaW5n IGZhY2lsaX RpZXMgdG8g cHJvZHVjZS BpdHMgcGhh cm1hY2V1dG ljYWwgcHJv ZHVjdHMgYX QgaGlnaCBx dWFsaXR5IG FuZCBlZmZp Y2llbmN5Lj xicj4zLiBN YXJrZXRpbm cgYW5kIHNh bGVzOiBUYW tlZGEgbWFy a2V0cyBhbm Qgc2VsbHMg aXRzIHByb2 R1Y3RzIHRv IGhlYWx0aG NhcmUgcHJv ZmVzc2lvbm FscyBhbmQg cGF0aWVudH MgZ2xvYmFs bHkgdGhyb3 VnaCB2YXJp b3VzIGNoYW 5uZWxzLCBp bmNsdWRpbm cgc2FsZXMg cmVwcmVzZW 50YXRpdmVz LCBkaWdpdG FsIG1hcmtl dGluZywgYW 5kIHBhcnRu ZXJzaGlwcy B3aXRoIGhl YWx0aGNhcm Ugb3JnYW5p emF0aW9ucy 48YnI+NC4g RGl2ZXJzaW ZpY2F0aW9u OiBUYWtlZG EgaGFzIGEg ZGl2ZXJzZS Bwb3J0Zm9s aW8gb2YgcG hhcm1hY2V1 dGljYWwgcH JvZHVjdHMs IHJhbmdpbm cgZnJvbSBw cmVzY3JpcH Rpb24gbWVk aWNpbmVzIH RvIG92ZXIt dGhlLWNvdW 50ZXIgYW5k IGNvbnN1bW VyIGhlYWx0 aGNhcmUgcH JvZHVjdHMu PGJyPjUuIE dlb2dyYXBo aWMgZXhwYW 5zaW9uOiBU YWtlZGEgb3 BlcmF0ZXMg aW4gb3Zlci A4MCBjb3Vu dHJpZXMgYW 5kIGNvbnRp bnVlcyB0by BleHBhbmQg aXRzIHByZX NlbmNlIGlu IGVtZXJnaW 5nIG1hcmtl dHMsIHBhcn RpY3VsYXJs eSBpbiBBc2 lhIGFuZCBM YXRpbiBBbW VyaWNhLjxi cj42LiBTdH JhdGVnaWMg cGFydG5lcn NoaXBzIGFu ZCBhY3F1aX NpdGlvbnM6 IFRha2VkYS Bjb2xsYWJv cmF0ZXMgd2 l0aCBvdGhl ciBwaGFybW FjZXV0aWNh bCBjb21wYW 5pZXMgYW5k IHJlc2Vhcm NoIGluc3Rp dHV0aW9ucy B0byBkZXZl bG9wIG5ldy B0cmVhdG1l bnRzIGFuZC B0ZWNobm9s b2dpZXMuIF RoZSBjb21w YW55IGFsc2 8gYWNxdWly ZXMgb3RoZX IgY29tcGFu aWVzIHRvIG V4cGFuZCBp dHMgcHJvZH VjdCBwb3J0 Zm9saW8gYW 5kIGdlb2dy YXBoaWMgcm VhY2guPGJy PjcuIFBhdG llbnQtY2Vu dHJpYyBhcH Byb2FjaDog VGFrZWRhIG ZvY3VzZXMg b24gdW5kZX JzdGFuZGlu ZyBwYXRpZW 50cycgbmVl ZHMgYW5kIH dvcmtzIHRv IGRldmVsb3 AgdHJlYXRt ZW50cyB0aG F0IG1lZXQg dGhvc2Ugbm VlZHMuIFRo ZSBjb21wYW 55IGFsc28g aW52ZXN0cy BpbiBwYXRp ZW50IGVkdW NhdGlvbiBh bmQgYWNjZX NzIHByb2dy YW1zIHRvIG 1ha2UgdHJl YXRtZW50cy Btb3JlIGFj Y2Vzc2libG UgdG8gdGhv c2UgaW4gbm VlZC48YnI+ T3ZlcmFsbC wgVGFrZWRh J3MgYnVzaW 5lc3MgbW9k ZWwgaXMgY2 VudGVyZWQg b24gaW5ub3 ZhdGlvbiwg c3RyYXRlZ2 ljIHBhcnRu ZXJzaGlwcy wgYW5kIGEg cGF0aWVudC 1jZW50cmlj IGFwcHJvYW NoIHRvIGJy aW5nIGxpZm UtY2hhbmdp bmcgbWVkaW NpbmVzIHRv IHBlb3BsZS Bhcm91bmQg dGhlIHdvcm xkLg==

AI has the potential to impact the Takeda Pharmaceutical company’s products, services, and competitive positioning in several ways, though whether it poses a material threat depends on the specific context.
1. Substitution: AI technologies can enhance drug discovery, development, and personalized medicine. While this does not directly substitute Takeda’s products, it could lead to the emergence of new competitors who leverage AI to develop innovative therapies more quickly and efficiently. If Takeda fails to integrate AI into its processes, it risks falling behind rivals who adopt these technologies effectively.
2. Disintermediation: In the pharmaceutical industry, disintermediation typically involves removing traditional intermediaries in the supply chain or healthcare delivery. AI can facilitate direct-to-consumer models, data-driven patient engagement, and more efficient clinical trial processes. Takeda may need to adapt its business model to maintain relevance and actively engage patients, healthcare providers, and payors directly, or else risk losing market share to more agile companies that utilize AI effectively.
3. Margin Pressure: AI can drive down costs in drug development through improved efficiencies and reduced time-to-market. If competitors leverage AI to create lower-cost therapies without sacrificing quality, it could exert margin pressure on Takeda’s portfolio. Furthermore, AI-driven innovations may lead to price competition within the industry, pushing down profit margins for established products if not countered by enhanced value propositions or innovative pricing strategies.
In summary, while AI presents several opportunities for Takeda to enhance its operations, it also introduces challenges that could affect its competitive positioning, particularly if competitors embrace AI more rapidly or effectively. The response of Takeda in integrating AI into its strategy will be crucial in determining whether these challenges materialize into significant threats.

The sensitivity of Takeda Pharmaceutical company’s earnings, cash flow, and valuation to changes in interest rates can be assessed through several key factors:
1. Cost of Debt: Takeda, like many companies, utilizes debt financing to support its operations and growth strategies. An increase in interest rates generally leads to higher borrowing costs, which can reduce net income and free cash flow. Conversely, lower interest rates may benefit the company by reducing interest expenses.
2. Discount Rate in Valuation: When estimating the present value of future cash flows in valuation models such as discounted cash flow (DCF), an increase in interest rates raises the discount rate. This decrease in present value can negatively impact the company’s overall valuation. Conversely, lower rates could increase the present value of cash flows, making the company seem more valuable.
3. Investment Decisions: Interest rates influence investment decisions for capital projects and R&D expenditures. Higher rates may lead Takeda to reconsider or delay investments when the cost of financing is higher. This could affect future growth rates and profitability.
4. Consumer Behavior and Drug Pricing: Changes in interest rates can also impact consumer behavior, particularly in markets reliant on financing, such as healthcare. If rates increase significantly, there may be reduced demand for medicines, affecting sales revenues and earnings.
5. Currency Sensitivity: Interest rate changes can affect currency values, particularly if Takeda operates in multiple countries. A stronger domestic currency could impact foreign revenues when converted back to the home currency, potentially affecting earnings.
Overall, while Takeda’s earnings, cash flow, and valuation can be sensitive to changes in interest rates, the extent of that sensitivity depends on various external and internal factors, including the company’s capital structure, market conditions, and operating strategies.

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3MvVz hVeWd5Y2dj ekVBMVhsRE 5nNjIud2Vi cCIgYWx0PS JUYWtlZGEg UGhhcm1hY2 V1dGljYWwi IHRpdGxlPS JUYWtlZGEg UGhhcm1hY2 V1dGljYWwi ICBjbGFzcz 0iaW1nLWZs dWlkIiBoZW lnaHQ9OTAg d2lkdGg9OT AgbG9hZGlu Zz0nbGF6eS cgc3R5bGU9 J2JvcmRlci 1yYWRpdXM6 IDZweDsnPg oKICAgICAg ICAgICAgIC AgICAgICA8 ZGl2IHN0eW xlPSdmbGV4 OiAxOyB0ZX h0LWFsaWdu OiBjZW50ZX I7IG1hcmdp bi1sZWZ0Oi A1cHg7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgPHAgc3R5 bGU9J2Zvbn Qtc2l6ZTog MjZweDsgY2 9sb3I6ICMz MzM7IG1hcm dpbi1ib3R0 b206IDE1cH g7Jz4KICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIPCfk4gg V2FudCB0by ByZWFkIG1v cmUgYWJvdX QgVGFrZWRh IFBoYXJtYW NldXRpY2Fs PwogICAgIC AgICAgICAg ICAgICAgIC AgICA8L3A+ CgogICAgIC AgICAgICAg ICAgICAgIC AgICA8YSBo cmVmPSdpbm RleC5waHA/ cGFnZT1zaW dudXAnIHN0 eWxlPScKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGJhY2 tncm91bmQt Y29sb3I6IC MwMDdCRkY7 CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBj b2xvcjogI2 ZmZjsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH ggMjBweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIGJv cmRlci1yYW RpdXM6IDVw eDsKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IHRleHQtZG Vjb3JhdGlv bjogbm9uZT sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG ZvbnQtd2Vp Z2h0OiBib2 xkOwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgbWFyZ2lu LXJpZ2h0Oi AxMHB4Owog ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgdHJh bnNpdGlvbj ogYmFja2dy b3VuZC1jb2 xvciAwLjNz IGVhc2U7Jw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgb2 5tb3VzZW92 ZXI9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA1Nm IzIicKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIG9ubW91 c2VvdXQ9J3 RoaXMuc3R5 bGUuYmFja2 dyb3VuZENv bG9yPSIjMD A3QkZGIic+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBT aWduIHVwIG ZvciBmcmVl CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDwvYT4K CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDxzcGFu IHN0eWxlPS dtYXJnaW46 IDAgOHB4Oy Bjb2xvcjog IzU1NTsnPm 9yPC9zcGFu PgoKICAgIC AgICAgICAg ICAgICAgIC AgICAgPGEg aHJlZj0naW 5kZXgucGhw P3BhZ2U9bG 9naW4nIHN0 eWxlPScKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGNvbG 9yOiAjMDA3 QkZGOwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgdGV4dC 1kZWNvcmF0 aW9uOiB1bm RlcmxpbmU7 CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBm b250LXdlaW dodDogNTAw Oyc+CiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICBsb2cgaW 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgPC9hPg oKCiAgICAg ICAgICAgIC AgICAgICAg ICAgIDxwIH N0eWxlPSdt YXJnaW4tdG 9wOiAxNXB4 OyBmb250LX NpemU6IDEz cHg7IGZvbn Qtd2VpZ2h0 OiBib2xkOy Bjb2xvcjog I2QzMmYyZj snPgogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC Ag8J+SoSBM ZWFybiBzbW FydGVyIHN0 b2NrIHBpY2 tzIHdpdGgg PGk+IlRoZS BDaGVja2xp c3QgVmFsdW UgSW52ZXN0 b3Ig4oCUIE EgU21hcnRl ciBXYXkgdG 8gUGljayBT dG9ja3MiPC 9pPgogICAg ICAgICAgIC AgICAgICAg ICAgICA8L3 A+CgogICAg ICAgICAgIC AgICAgICAg ICAgICA8IS 0tCiAgICAg ICAgICAgIC AgICAgICAg ICAgIDxkaX Ygc3R5bGU9 J21hcmdpbi 10b3A6IDEy cHg7IGZvbn Qtc2l6ZTog MTNweDsgY2 9sb3I6ICM0 NDQ7Jz4KIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIFNpZ2 4gdXAgbm93 IGFuZCBnZX Qgb3VyIGZy ZWUgZUJvb2 sgCiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC A8Yj5UaGUg Q2hlY2tsaX N0IFZhbHVl IEludmVzdG 9yIOKAlCBB IFNtYXJ0ZX IgV2F5IHRv IFBpY2sgU3 RvY2tzPC9i PgogICAgIC AgICAgICAg ICAgICAgIC AgICA8L2Rp dj4KICAgIC AgICAgICAg ICAgICAgIC AgICAgLS0+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDwhLS0K ICAgICAgIC AgICAgICAg ICAgICAgIC AgPGRpdiBz dHlsZT0nbW FyZ2luLXRv cDogMTZweD sgZm9udC1z aXplOiAxNH B4OyBjb2xv cjogIzQ0ND sgZm9udC1m YW1pbHk6IC 1hcHBsZS1z eXN0ZW0sIE JsaW5rTWFj U3lzdGVtRm 9udCwgU2Vn b2UgVUksIF JvYm90bywg SGVsdmV0aW NhIE5ldWUs IHNhbnMtc2 VyaWY7IGxp bmUtaGVpZ2 h0OiAxLjY7 Jz4KICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IEhhdmUgeW 91IGhlYXJk IGFib3V0IG 91ciBzaG9y dCA8c3Ryb2 5nIHN0eWxl PSdmb250LX dlaWdodDog NjAwOyc+RG FpbHkgVmlk ZW8gTmV3c2 xldHRlcjwv c3Ryb25nPj 8KICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgID xhIGhyZWY9 J2h0dHBzOi 8vd3d3Lmlu c2lnaHRmdW x2YWx1ZS5j b20vbmV3c2 xldHRlci5w aHAnIHRhcm dldD0nX2Js YW5rJyBzdH lsZT0nY29s b3I6ICMwMD dCRkY7IHRl eHQtZGVjb3 JhdGlvbjog bm9uZTsgZm 9udC13ZWln aHQ6IDUwMD sgbWFyZ2lu LWxlZnQ6ID ZweDsnPgog ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IEZpbmQgb3 V0IG1vcmUK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIDwv YT4KICAgIC AgICAgICAg ICAgICAgIC AgICAgPC9k aXY+CiAgIC AgICAgICAg ICAgICAgIC AgICAgIC0t PgogICAgIC AgICAgICAg ICAgICAgID wvZGl2Pgog ICAgICAgIC AgICAgICAg PC9kaXY+Ci AgICAgICAg ICAgIDwvZG l2PgogICAg ICAgICAgIC AKICAgICAg ICAKICAgIC AgICA8c3Bh biBjbGFzcz 0nYmx1cnJl ZC10ZXh0Jz 4KICAgICAg ICAgICAgTV M0Z1ZHRnJa VyBSaElGQm 9ZWEp0IFlX TmxkWFJwWT IgRnNJR2x6 SUdFZyBTbU Z3WVc1bGMy IFVnYlhWc2 RHbHUgWVhS cGIyNWhiQy BCd2FHRnli V0ZqIFpYVj BhV05oYkMg QmpiMjF3WV c1NSBMQ0Jv WldGa2NYIF ZoY25SbGNt VmsgSUdsdU lGUnZhMyBs dkxDQktZWE JoIGJpNGdT WFFnYVggTW diMjVsSUc5 bSBJSFJvWl NCc1lYIEpu WlhOMElIQm 8gWVhKdFlX TmxkWCBScF kyRnNJR052 IGJYQmhibW xsY3kgQnBi aUIwYUdVZy BkMjl5YkdR Z1luIGtnY2 1WMlpXNTEg WlM0OFluSS tNaSA0Z1ZH aGxJR052IG JYQmhibmtn ZDIgRnpJR1 p2ZFc1ayBa V1FnYVc0Z0 1UIGM0TVNC aWVTQkQgYU c5aVpXa2dW RyBGclpXUm hJRWtnIFlX NWtJSGRoY3 kgQnBibWww YVdGcyBiSG tnWTJGc2JH IFZrSUZSaG EyVmsgWVNC RGFHOWlaVy BrZ1VHaGhj bTFoIFkyVj FkR2xqWVcg d2dVMmh2Y0 M0ZyBTWFFn ZDJGeklHIE VnYzIxaGJH d2cgY0doaG NtMWhZMyBr Z2FXNGdSRz l6IGFHOXRZ V05vYVMgd2 dUM05oYTJF cyBJRXBoY0 dGdUxqIHhp Y2o0ekxpQl UgWVd0bFpH RWdVRyBoaG NtMWhZMlYx IGRHbGpZV3 dnWW0gVmpZ VzFsSUdFZy BjSFZpYkds aklHIE52Yl hCaGJua2cg YVc0Z01Uaz BPUyBCaGJt UWdkMkZ6IE lHeHBjM1Js WkMgQnZiaU IwYUdVZyBW RzlyZVc4Z1 UzIFJ2WTJz Z1JYaGogYU dGdVoyVXVQ RyBKeVBqUX VJRlJoIGEy VmtZZUtBbV ggTWdiV0Zw YmlCbSBiMk 4xY3lCcGN5 IEJ5WlhObF lYSmogYUNC aGJtUWdaRy BWMlpXeHZj RzFsIGJuUW dhVzRnZEcg aGxJR1pwWl d4ayBjeUJ2 WmlCdmJtIE 52Ykc5bmVT d2cgWjJGem RISnZaVyA1 MFpYSnZiRz luIGVTd2dZ VzVrSUcgTm xiblJ5WVd3 ZyBibVZ5ZG 05MWN5IEJ6 ZVhOMFpXMG cgWkdsemIz SmtaWCBKek xpQkpkQ0Jo IGJITnZJSE J5YjIgUjFZ MlZ6SUhaaC BZMk5wYm1W eklHIEZ1Wk NCdmRtVnkg TFhSb1pTMW piMyBWdWRH VnlJRzFsIF pHbGpZWFJw YjIgNXpMan hpY2o0MSBM aUJVYUdVZ1 kyIDl0Y0dG dWVTQm8gWV hNZ1lTQm5i RyA5aVlXd2 djSEpsIGMy VnVZMlVzSU ggZHBkR2dn YjNCbCBjbU YwYVc5dWN5 IEJwYmlCdm RtVnkgSURn d0lHTnZkVy A1MGNtbGxj eUJoIGJtUW djbVZuYVcg OXVjeXdnYV c1aiBiSFZr YVc1bklIIF JvWlNCVmJt bDAgWldRZ1 UzUmhkRyBW ekxDQkZkWE p2IGNHVXNJ R0Z1WkMgQk JjMmxoTGp4 aSBjajQyTG lCVVlXIHRs WkdFZ2FHRn ogSUdFZ2Mz UnliMiA1bk lHTnZiVzFw IGRHMWxibl FnZEcgOGdj M1Z6ZEdGcC BibUZpYVd4 cGRIIGtnWV c1a0lIZGgg Y3lCc2FYTj BaVyBRZ2FX NGdkR2hsIE lFUnZkeUJL YjIgNWxjeU JUZFhOMCBZ V2x1WVdKcG JHIGwwZVNC SmJtUnAgWT JWeklHWnZj aSBBeE1TQm piMjV6IFpX TjFkR2wyWl MgQjVaV0Z5 Y3k0OCBZbk krTnk0Z1NX IDRnTWpBd0 9Dd2cgVkdG clpXUmhJRy BGamNYVnBj bVZrIElFMX BiR3hsYm0g NXBkVzBnVU doaCBjbTFo WTJWMWRHIG xqWVd4ekxD QmggSUd4bF lXUnBibSBj Z1ltbHZjR2 hoIGNtMWhZ MlYxZEcgbG pZV3dnWTI5 dCBjR0Z1ZV NCbWIyIE4x YzJWa0lHOX UgSUhSb1pT QmtaWCBabG JHOXdiV1Z1 IGRDQnZaaU J2Ym0gTnZi RzluZVNCMC BjbVZoZEcx bGJuIFJ6TG p4aWNqNDQg TGlCVVlXdG xaRyBFZ2FY TWdhVzUyIG IyeDJaV1Fn YVcgNGdkbU Z5YVc5MSBj eUJ3WVhKMG JtIFZ5YzJo cGNITWcgWV c1a0lHTnZi RyB4aFltOX lZWFJwIGIy NXpJSGRwZE cgZ2diM1Jv WlhJZyBjR2 hoY20xaFky IFYxZEdsal lXd2cgWTI5 dGNHRnVhVy BWekxDQmhZ MkZrIFpXMX BZeUJwYm4g TjBhWFIxZE dsdiBibk1z SUdGdVpDIE J5WlhObFlY SmogYUNCdm NtZGhibSBs NllYUnBiMj V6IExqeGlj ajQ1TGkgQl VhR1VnWTI5 dCBjR0Z1ZV NCaGJIIE52 SUdoaGN5Qm ggSUhOMGNt OXVaeSBCbW IyTjFjeUJ2 IGJpQnBibT V2ZG0gRjBh Vzl1SUdGdS BaQ0JwYm5a bGMzIFJ6SU dobFlYWnAg YkhrZ2FXNG djbSBWelpX RnlZMmdnIF lXNWtJR1Js ZG0gVnNiM0 J0Wlc1MCBM aUJKYmlBeU 1EIEl3TENC cGRDQnogY0 dWdWRDQnZk bSBWeUlDUT BJR0pwIGJH eHBiMjRnYj IgNGdVaVpF TGp4aSBjaj R4TUM0Z1ZH IEZyWldSaE lHaGggY3lC aElISnBZMi BnZ2FHbHpk Rzl5IGVTQm hibVFnYUcg RnpJSEJzWV hsbCBaQ0Jo SUhOcFoyID VwWm1sallX NTAgSUhKdm JHVWdhVyA0 Z2RHaGxJR1 JsIGRtVnNi M0J0WlcgNT BJRzltSUhS byBaU0J3YU dGeWJXIEZq WlhWMGFXTm ggYkNCcGJt UjFjMyBSeW VTQnBiaUJL IFlYQmhiaT RnU1ggUWdh R0Z6SUdKbC BaVzRnY21W amIyIGR1YV hwbFpDQjMg YVhSb0lHNT FiVyBWeWIz VnpJR0YzIF lYSmtjeUJo Ym0gUWdhRz l1YjNKeiBJ RzkyWlhJZ2 RHIGhsSUhs bFlYSnogTG p4aWNqNHhN UyA0Z1ZHRn JaV1JoIElH aGhjeUJoSU cgTnZjbkJ2 Y21GMCBaU0 J3YUdsc2Iz IE52Y0doNU lHTmggYkd4 bFpDQlVZVy B0bFpHRXRh WE50IExDQj NhR2xqYUMg QmxiWEJvWV hOcCBlbVZ6 SUhSb1pTIE JqYjIxd1lX NTUgNG9DWm N5QmpiMiAx dGFYUnRaVz UwIElIUnZJ SEJoZEcgbG xiblJ6TENC bCBiWEJzYj NsbFpYIE1z SUdGdVpDQn ogYjJOcFpY UjVMaiB4aW NqNHhNaTRn IFZHaGxJR0 52YlggQmhi bmtnYUdGei BJR1poWTJW a0lHIE5vWV d4c1pXNW4g WlhNZ2FXNG djbSBWalpX NTBJSGxsIF lYSnpMQ0Jw Ym0gTnNkV1 JwYm1jZyBj R0YwWlc1ME lHIFY0Y0ds eVlYUnAgYj I1eklHRnVa QyBCc1pXZG hiQ0JwIGMz TjFaWE1nY2 0gVm5ZWEpr YVc1biBJSE 52YldVZ2Iy IFlnYVhSek lHMWwgWkds allYUnBiMi A1ekxpQkli M2RsIGRtVn lMQ0JwZEMg QmpiMjUwYV c1MSBaWE1n ZEc4Z1ltIF VnWVNCdFlX cHYgY2lCd2 JHRjVaWCBJ Z2FXNGdkR2 hsIElHZHNi MkpoYkMgQn dhR0Z5YldG aiBaWFYwYV dOaGJDIEJ0 WVhKclpYUX UgUEdKeVBq RXpMaSBCSm JpQXlNREl4 IExDQlVZV3 RsWkcgRWdZ VzV1YjNWdS BZMlZrSUds MGN5IEJwYm 5SbGJuUnAg YjI0Z2RHOG dZbSBWamIy MWxJR0VnIF oyeHZZbUZz SUcgeGxZV1 JsY2lCcCBi aUJ5WVhKbE lHIFJwYzJW aGMyVnogSU hkcGRHZ2dZ UyBCbmIyRn NJSFJ2IElH eGhkVzVqYU MgQXpNQ0J5 WVhKbCBJR1 JwYzJWaGMy IFVnZEdobG NtRncgYVdW eklHSjVJRC BJd016QXVQ R0p5IFBqRT BMaUJVWVcg dGxaR0VnYV hNZyBZV3h6 YnlCcmJtID kzYmlCbWIz SWcgYVhSek lITjBjbSA5 dVp5QmpiM0 p3IGIzSmhk R1VnWTMgVn NkSFZ5WlNC aCBibVFnYU dGeklHIEps Wlc0Z2NtVm ogYjJkdWFY cGxaQyBCaG N5QnZibVVn IGIyWWdkR2 hsSUggZHZj bXhrNG9DWi BjeUJ0YjNO MElHIEZrYl dseVpXUWcg WTI5dGNHRn VhVyBWeklH SjVJRVp2IG NuUjFibVVn VFcgRm5ZWH BwYm1VZyBa bTl5SURFd0 lHIE52Ym5O bFkzVjAgYV habElIbGxZ WCBKekxqeG ljajR4IE5T NGdTVzRnWV cgUmthWFJw YjI0ZyBkRz hnY0doaGNt IDFoWTJWMW RHbGogWVd4 ekxDQlVZVy B0bFpHRWdh WE1nIFlXeH pieUJwYm4g WnZiSFpsWk NCcCBiaUIy WVhKcGIzIF Z6SUc5MGFH VnkgSUdKMW MybHVaWCBO elpYTXNJR2 x1IFkyeDFa R2x1WnkgQm 1iMjlrSUhC eSBiMlIxWT NSekxDIEJv WldGc2RHZ2 cgWVc1a0lH SmxZWCBWMG VTQnpkWEJ3 IGJHVnRaVz UwY3kgd2dZ VzVrSUcxbC BaR2xqWVd3 Z1pHIFYyYV dObGN5ND0K ICAgICAgIC A8L3NwYW4+ CiAgICAgIC AgCiAgICAg ICAg